Gilead Sciences stock (US3755581036): Biotech giant eyes growth in HIV and oncology markets

Gilead Sciences reports solid first?quarter results, highlighting continued strength in HIV and hepatitis therapies while advancing its oncology pipeline.

Gilead Sciences has reported its first?quarter 2026 results, underscoring the company’s ongoing reliance on its core HIV and hepatitis franchises while it seeks to broaden its footprint in oncology and other specialty areas. Revenue for the period came in at about 7.8 billion USD, up roughly 3 percent year?over?year, driven by steady demand for its antiviral products and a modest contribution from newer oncology assets, according to Gilead press release as of May 7, 2026.

Net income for the quarter was approximately 2.1 billion USD, or 1.68 USD per diluted share, reflecting both operational leverage and a lower effective tax rate compared with the prior?year quarter. Management reiterated its full?year 2026 revenue guidance in the mid?30?billion?USD range, signaling confidence in the durability of its HIV and hepatitis C franchises despite increasing competition and patent?expiry pressures in some markets, according to the same release.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gilead Sciences, Inc.
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: Foster City, California, United States
• Core markets: United States, Europe, Japan, and emerging markets
• Key revenue drivers: HIV therapies, hepatitis B and C treatments, oncology and inflammation products
• Home exchange/listing venue: Nasdaq (ticker: GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences operates as a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for life?threatening diseases. The company’s business model centers on high?margin, patent?protected therapies in virology, particularly HIV and hepatitis B and C, while it increasingly invests in oncology, inflammation, and other specialty areas. This strategy allows Gilead to generate substantial cash flow from established products, which it then reinvests into research and development and targeted acquisitions.

The company’s virology portfolio includes leading HIV regimens such as Biktarvy, Descovy, and Truvada, which together account for a large share of global HIV treatment prescriptions. In hepatitis, Gilead’s once?daily single?tablet regimens for hepatitis C, such as Epclusa and Vosevi, helped transform the standard of care and remain important revenue contributors, even as cure rates have reduced the overall patient pool. Gilead also markets Vemlidy for chronic hepatitis B, a long?term treatment that benefits from recurring prescriptions.

On the oncology side, Gilead’s cell?therapy subsidiary Kite Pharma markets Yescarta and Tecartus, chimeric antigen receptor (CAR) T?cell therapies for certain lymphomas and leukemias. These products command premium prices and are positioned in niche but high?unmet?need indications, reinforcing Gilead’s shift toward more complex, biologic?based treatments. The company continues to expand its oncology pipeline through internal R&D and partnerships, aiming to diversify beyond its traditional virology base.

Main revenue and product drivers for Gilead Sciences

HIV therapies remain the single largest revenue driver for Gilead Sciences, with Biktarvy alone generating several billion dollars annually. The regimen’s once?daily dosing, favorable safety profile, and broad label approvals have helped it gain share against older and competing regimens. Descovy and Truvada also contribute meaningfully, both as treatment options and as components of pre?exposure prophylaxis (PrEP) for HIV prevention, particularly in the United States.

Hepatitis C and hepatitis B products continue to provide a stable, if gradually declining, revenue stream. While the hepatitis C market has contracted as many patients have been cured, Gilead still benefits from residual demand and from pricing power in certain regions. In hepatitis B, Vemlidy offers a differentiated profile versus older nucleos(t)ide analogs, supporting continued uptake in key markets. Together, these virology franchises underpin Gilead’s profitability and provide the financial cushion needed to fund its oncology and inflammation initiatives.

Oncology and inflammation are emerging as increasingly important growth vectors. Kite’s CAR?T products have shown strong clinical outcomes in relapsed or refractory lymphomas and leukemias, and Gilead is investing in next?generation cell therapies and solid?tumor programs. In inflammation, the company markets Trodelvy for certain breast and urothelial cancers and is exploring additional indications. These newer assets are still smaller in absolute revenue terms but represent a strategic pivot toward higher?growth, higher?risk therapeutic areas.

Conclusion

Gilead Sciences continues to balance the cash?flow stability of its established HIV and hepatitis franchises with the growth potential of its oncology and inflammation pipelines. The company’s first?quarter 2026 results reflect this dual?track strategy, with modest top?line growth and solid profitability supported by core virology products and incremental contributions from newer therapies. For investors, Gilead offers exposure to a diversified biotech portfolio with a strong presence in the United States and other major markets.

At the same time, the stock faces headwinds from patent expiries, generic competition, and the inherently high risk and cost of drug development, particularly in oncology. Pricing pressures and evolving reimbursement policies in the United States and Europe add further uncertainty. As a result, Gilead may appeal more to investors seeking a relatively mature biotech with recurring revenue streams and a track record of innovation, while those focused on high?beta growth may weigh the company’s slower pace of pipeline maturation against its financial resilience.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.